Cardiovascular Assessment of Ponatinib as Third Line Treatment Option in Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib and Bosutinib (CarPAs)
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Acronyms CarPAs
- 10 Mar 2022 Status changed from not yet recruiting to discontinued.
- 12 Jan 2021 Status changed from recruiting to not yet recruiting.
- 11 Dec 2020 New trial record